North America Injection Pen Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)
North America Injection Pen Market: by Type (Reusable Injection Pen, Disposable Injection Pen), Application (Diabetes, Growth Hormone Therapy, Fertility, Osteoporosis, Other Applications), Distribution Channels (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Diabetes Clinics, Others), Technology (Smart Injection Pen, Conventional Injection Pen), Organization Size (Small, Medium, Large) and By North America Historical & Forecast Period (2020-2035) Comprehensive Study 2025
Last Updated: 31-07-2025 | Format: PDF | Report ID:20486 | Author: Ankit
The North America Injection Pen Market is experiencing robust growth, fueled by rising chronic disease prevalence and advances in injection pen technologies such as smart and connected devices. Demand for user-friendly, portable, and accurate drug delivery systems is propelling market expansion. Key applications include diabetes management, growth hormone therapy, and fertility treatments. Rapid digital integration and focus on patient-centric solutions are further driving development across the US, Canada, and Mexico. The market reflects a diverse competitive landscape, with leading players innovating to capture niche segments and respond to evolving healthcare needs.
Latest Market Dynamics
Key Drivers
Rising incidence of diabetes and other chronic diseases, prompting an increased demand for convenient drug delivery systems. For example, Novo Nordisk has expanded its range of insulin pens in the US market in 2025 to address this demand.
Growth in digital health technology integration. Companies like Eli Lilly launched smart, app-connected pens in 2025, enabling better monitoring and data integration for both patients and clinicians.
Key Trends
Rapid adoption of smart injection pens with real-time monitoring features, as seen with Companion Medical's InPen expansion into Canadian pharmacies in 2025.
Customization of injection pens for specific therapies, highlighted by Ypsomed's launch of therapy-specific pens for growth hormone and fertility in North America.
Key Opportunities
Expansion of connected devices catering to remote monitoring and telemedicine, with Sanofi launching Bluetooth-enabled pens in US clinics in early 2025.
Entry into untapped therapeutic areas such as oncology, demonstrated by Becton Dickinson's introduction of oncology-targeted injection pens in June 2025.
Key Challenges
Complex regulatory landscape leading to delayed approvals. For instance, Biocon faced delays in US FDA approvals for their next-gen insulin pens in 2025.
High cost and reimbursement hurdles, impacting access for small clinics and less-insured populations, as reported by Haselmeier's North American distribution partners.
Key Restraints
Concerns about product recalls and device malfunctions, with Merck issuing a voluntary recall in July 2025 for select pen batches due to dosing inaccuracies.
Limited awareness and acceptance in rural and elderly demographics, as identified by Owen Mumford's 2025 US patient survey.
North America Injection Pen Market Share by Type, 2025
In 2025, the North American Injection Pen Market is predominantly led by disposable injection pens, which cater to the need for hygiene, convenience, and ease of use, particularly for diabetes and self-administered therapies. Reusable injection pens maintain a substantial market share among long-term or multi-use patients, favored in clinical settings due to their cost-effectiveness over time. Smart injection pens are rapidly gaining ground due to increasing integration of digital health technologies, streamlining care through data connectivity and app integration. The growth trajectory for smart pens is particularly strong among tech-savvy and younger patient populations, indicating a shift towards digital therapeutic management.
North America Injection Pen Market Share by Application, 2025
The primary application of injection pens in North America remains diabetes management, commanding over half of the market due to persistent high prevalence and growing awareness. Growth hormone therapy and fertility treatments follow as significant market segments, driven by advancements in pediatric endocrinology and reproductive medicine. Emerging application areas, such as osteoporosis and oncology, are expected to see continued growth as new pen technologies improve administration ease and patient adherence. The dominance of diabetes is reinforced by ongoing innovation in insulin delivery mechanisms and broad insurance coverage across the US and Canada, while niche segments benefit from growing therapeutic adoption and targeted product launches.
North America Injection Pen Market Revenue (USD Million), 2020-2035
The North America Injection Pen Market is projected to see steady year-on-year growth, rising from $1,850 Million in 2020 to $3,420 Million in 2025 and expected to approach $6,960 Million by 2035. This revenue trajectory reflects rising chronic disease burden, technological advancements, and increased penetration in both urban and rural markets. Top market contributors include the US, which accounts for the largest share due to early adoption of innovative technologies and robust healthcare access, followed by Canada and Mexico, both benefitting from focused product launches and improved distribution networks. The high CAGR is indicative of consistent innovation and rising usage across diverse therapeutic categories.
North America Injection Pen Market Year-on-Year Growth (%), 2020-2035
Year-on-year growth rates in the North America Injection Pen Market are projected to peak at around 10.5% during the period 2025-2027, driven by the widespread adoption of smart connected devices and the expansion of patient education initiatives. The growth rate is anticipated to moderate gradually to around 6.2% by 2035 as the market matures and technology uptake plateaus. Much of the early surge can be attributed to aggressive market entry strategies by leading pharmaceutical and medtech players, and the ongoing digital transformation in healthcare delivery, while later years reflect the sector’s stabilization and sustained usage.
North America Injection Pen Market Share by Country, 2025
In 2025, the United States holds the dominant position within the North America Injection Pen Market, generating 77% of total revenue, supported by advanced healthcare infrastructure, widespread insurance coverage, and a high prevalence of diabetes and growth hormone-related conditions. Canada follows with 16%, benefitting from increased investment in public health initiatives and growing adoption of connected health devices. Mexico accounts for 7%, a share that is expected to grow as local distribution expands and chronic care needs increase. This country-wise distribution highlights the US as the key driver of technological innovation and early market adoption, while Canada and Mexico represent growth opportunities through targeted outreach and product accessibility.
North America Injection Pen Market Players Share, 2025
The market is characterized by the presence of several key multinational players. Novo Nordisk leads with 30% market share, leveraging its extensive product range and strong distribution networks. Sanofi and Eli Lilly are close contenders, holding 22% and 18% respectively, each investing heavily in digital ecosystem developments for pens. Ypsomed and Becton Dickinson follow with 11% and 8%, focusing on innovative pen platforms and partnerships. The competitive landscape remains dynamic as companies compete on technological enhancements, product portfolio breadth, and patient-centric solutions.
North America Injection Pen Market Buyers Share, 2025
The largest buyer segment for injection pens in North America remains hospital pharmacies, accounting for 40% of purchases due to bulk procurement for institutional use. Retail pharmacies represent 26%, catering to patients managing chronic therapies at home. Online pharmacies, bolstered by telehealth growth and home delivery, have gained 18% share, while diabetes clinics (9%) and specialty/others (7%) account for the remainder. This segmentation underlines the importance of streamlined logistics, multi-channel distribution, and the growing importance of patient-directed purchasing behaviors.
Study Coverage
Metrics
Details
Years
2020-2035
Base Year
2025
Market Size
3420
Regions
United States, Canada, Mexico
Segments
By Type, By Application, By Distribution Channels, By Technology, By Organization Size
June 2024: Eli Lilly launched its latest smart insulin pen line in Canada with Bluetooth-connected features for remote monitoring.
July 2024: Merck issued a voluntary recall of select batches of its injection pens in the US due to dosing inconsistencies, reinforcing the need for robust quality control.
August 2024: Novo Nordisk announced a partnership with a leading US telehealth platform for enhanced direct-to-patient delivery services for injection pens.
September 2024: Ypsomed introduced customizable fertility injection pens, expanding its offerings for reproductive health in North America.
October 2024: Sanofi’s US operation launched a subscription program for their connected injection pen devices, targeting improved adherence in chronic disease management.
Frequently Asked Questions
About the Author
Ankit
Senior Research Consultant
Ankit is a Senior Research Consultant specializing in market research, industry analysis, and business consulting across Healthcare. Ankit brings a commercially grounded perspective to sectors shaped by changing demand, innovation, and competitive dynamics, helping turn complex market trends into clear strategic insights for business decision-makers. With 10+ years of experience across research, analytics, and strategic advisory roles, Ankit has helped organizations translate data into actionable growth strategies.
